



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In response to application of: William J. Rea, MD, et al  
Serial No.: 08/902,692  
Filed: July 30, 1997  
For: **AUTOGENOUS LYMPHATIC FACTOR FOR  
MODIFICATION OF T AND B LYMPHOCYTE PARAMETERS**

Attorney Docket: 16715/CIP  
Art Group Unit: 1644  
Examiner: Schwadron, R.

12/B  
M. J. J  
4/16/99

**AMENDMENT**

Honorable Commissioner of Patents  
and Trademarks  
Washington, D.C. 20231

Sir:

In response to the Office Action mailed February 12, 1999 and a short telephone interview on March 16, 1999, please amend the application as follows:

In the Title:

Please change the title to – Method Of Treating A Chemically Sensitive Individual –

In the Specification:

At page 1, line 13, please delete “normal”.

At page 3, line 7, delete “normal”.

At page 3, line 15, delete “normal”.

At page 6, lines 9-10, delete “normal (non-cancerous or otherwise dysfunctional)”.

At page 6, line 16, delete “normal”.

At page 8, line 22, delete “normal”.

Change(s) applied  
to document,

/E.C./

11/15/2012

In the Abstract of the Disclosure:

Please delete the entire text of the abstract in favor of the following new text:

– A method for treating a chemically sensitive individual is provided. The method includes the steps of: collecting a blood sample from the individual; isolating mixed T and B lymphocytes from the blood sample; propagating the isolated mixed T and B lymphocytes to obtain propagated lymphocytes; lysing the propagated lymphocytes to obtain a lysate; and administering the lysate to the individual. A therapeutic dose of the lysate can be determined by skin testing, and the dose can be